Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 212356, held by Strides Pharma. Triamcinolone Acetonide.
As of Nov 15, 2026, ANDA 212356 (Triamcinolone Acetonide), held by Strides Pharma, was first approved by FDA on Jun 1, 2020, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Triamcinolone Acetonide Ointment USP, 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 1, 2020 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Triamcinolone Acetonide0.05% · ointment;topical | Triamcinolone Acetonide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
